Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

3TOG

HIV-1 Protease - Epoxydic Inhibitor Complex (pH 9 - Monoclinic Crystal form P21)

Summary for 3TOG
Entry DOI10.2210/pdb3tog/pdb
Related PRD IDPRD_001019
DescriptorGag-Pol polyprotein, DIMETHYL SULFOXIDE, (S)-N-((2S,3S,4R,5R)-4-amino-3,5-dihydroxy-1,6-diphenylhexan-2-yl)-3-methyl-2-(2-phenoxyacetamido)butanamide, ... (4 entities in total)
Functional Keywordshiv pr, epoxide, in-crystal reaction, hydrolase, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
Biological sourceHuman immunodeficiency virus type 1 (BRU ISOLATE) (HIV-1)
Total number of polymer chains4
Total formula weight44264.42
Authors
Geremia, S.,Olajuyigbe, F.M.,Demitri, N. (deposition date: 2011-09-05, release date: 2012-08-15, Last modification date: 2023-09-13)
Primary citationOlajuyigbe, F.M.,Demitri, N.,De Zorzi, R.,Geremia, S.
Developing HIV-1 Protease Inhibitors through Stereospecific Reactions in Protein Crystals.
Molecules, 21:-, 2016
Cited by
PubMed Abstract: Protease inhibitors are key components in the chemotherapy of HIV infection. However, the appearance of viral mutants routinely compromises their clinical efficacy, creating a constant need for new and more potent inhibitors. Recently, a new class of epoxide-based inhibitors of HIV-1 protease was investigated and the configuration of the epoxide carbons was demonstrated to play a crucial role in determining the binding affinity. Here we report the comparison between three crystal structures at near-atomic resolution of HIV-1 protease in complex with the epoxide-based inhibitor, revealing an in-situ epoxide ring opening triggered by a pH change in the mother solution of the crystal. Increased pH in the crystal allows a stereospecific nucleophile attack of an ammonia molecule onto an epoxide carbon, with formation of a new inhibitor containing amino-alcohol functions. The described experiments open a pathway for the development of new stereospecific protease inhibitors from a reactive lead compound.
PubMed: 27809253
DOI: 10.3390/molecules21111458
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.24 Å)
Structure validation

247536

PDB entries from 2026-01-14

PDB statisticsPDBj update infoContact PDBjnumon